Pharvaris N.V. $PHVS Position Trimmed by Squarepoint Ops LLC

Key Points

• Squarepoint Ops LLC cut its Pharvaris stake by 53.7% in the second quarter, selling 51,755 shares and retaining 44,629 shares valued at approximately $1.54 million. Several other institutions initiated positions during the period.
• Analyst sentiment remains broadly positive: 13 analysts rate PHVS a Buy, one rates it Hold and one rates it Sell, producing a “Moderate Buy” consensus and an average price target of $59.87.
• PHVS opened at $38.06, near its 52-week high of $43.25, but the company missed quarterly EPS expectations with a loss of $0.81 versus the $0.75 consensus. Insider selling, including transactions by the CEO and other executives, totaled 186,655 shares worth about $6.87 million over the last quarter.

Squarepoint Ops LLC lowered its stake in Pharvaris N.V. (NASDAQ:PHVS - Free Report) by 53.7% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 44,629 shares of the company's stock after selling 51,755 shares during the period. Squarepoint Ops LLC owned approximately 0.07% of Pharvaris worth $1,543,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently modified their holdings of the company. Quantbot Technologies LP purchased a new stake in shares of Pharvaris during the second quarter valued at $41,000. CoreCap Advisors LLC purchased a new stake in Pharvaris during the second quarter valued at about $93,000. Nano Cap New Millennium Growth Fund L P purchased a new stake in Pharvaris during the fourth quarter valued at about $139,000. Public Employees Retirement System of Ohio acquired a new position in shares of Pharvaris in the second quarter worth about $196,000. Finally, Algert Global LLC acquired a new position in shares of Pharvaris in the second quarter worth about $238,000.

Wall Street Analyst Weigh In

PHVS has been the topic of a number of recent analyst reports. Oppenheimer restated an "outperform" rating and set a $75.00 price target on shares of Pharvaris in a report on Tuesday, September 8th. Wall Street Zen cut Pharvaris from a "hold" rating to a "sell" rating in a research report on Saturday, July 18th. Rosenblatt Securities set a $60.00 target price on Pharvaris in a report on Wednesday, September 9th. Guggenheim boosted their price objective on Pharvaris from $40.00 to $44.00 and gave the stock a "buy" rating in a research report on Thursday, September 10th. Finally, Citigroup reaffirmed a "market outperform" rating on shares of Pharvaris in a report on Wednesday, September 9th. Thirteen analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $59.87.

More Pharvaris News

Here are the key news stories impacting Pharvaris this week:

• Positive Sentiment: Pharvaris’ phase III data showed that once-daily extended-release deucrictibant reduced hereditary angioedema (HAE) attacks by 83%. The results support the company’s plans to pursue regulatory submissions in 2027 and strengthen the investment case for its lead drug candidate. PHVS Stock Rises 10% in a Month: What Is Driving the Rally?
• Positive Sentiment: Analyst expectations have improved, with the consensus price target reportedly raised 20.08% to $59.77. Recent coverage also includes RBC raising its target to $62 and maintaining an outperform rating, while the broader analyst consensus remains “Moderate Buy.” Pharvaris NV consensus price target raised 20.08% to $59.77
• Positive Sentiment: Recent institutional buying—including new positions from BlackRock and increased holdings by Alyeska Investment Group and Seven Fleet Capital—signals growing professional-investor interest in PHVS.
• Neutral Sentiment: Pharvaris presented at the Morgan Stanley 24th Annual Global Healthcare Conference, giving management another opportunity to discuss deucrictibant and the company’s development and regulatory strategy with institutional investors. The supplied transcript headline does not identify a separate new announcement. Pharvaris Presents at Morgan Stanley Global Healthcare Conference
• Negative Sentiment: Insider selling is a counterweight: CEO Berndt Modig sold 2,291 shares, President Peng Lu sold 15,000 shares, and insider Anne Lesage sold 30,000 shares for approximately $1.15 million. Lu’s sale was specifically described as covering tax withholding tied to vested equity, which reduces—but does not eliminate—the negative signal. Insider Selling: Pharvaris Insider Sells 30,000 Shares

Pharvaris Price Performance

Shares of NASDAQ PHVS opened at $38.06 on Wednesday. The firm has a market capitalization of $2.49 billion, a P/E ratio of -12.48 and a beta of -2.33. Pharvaris N.V. has a fifty-two week low of $20.65 and a fifty-two week high of $43.25. The company's 50 day simple moving average is $35.27 and its 200 day simple moving average is $31.56.

Pharvaris (NASDAQ:PHVS - Get Free Report) last posted its earnings results on Wednesday, August 12th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.06). Sell-side analysts expect that Pharvaris N.V. will post -3.12 EPS for the current fiscal year.

Insiders Place Their Bets

In other Pharvaris news, insider Anne Lesage sold 30,000 shares of the company's stock in a transaction on Thursday, September 10th. The shares were sold at an average price of $38.30, for a total value of $1,149,000.00. Following the transaction, the insider directly owned 56,450 shares in the company, valued at $2,162,035. The trade was a 34.70% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Berndt Modig sold 2,291 shares of the firm's stock in a transaction dated Monday, September 14th. The stock was sold at an average price of $39.40, for a total transaction of $90,265.40. Following the sale, the chief executive officer owned 128,334 shares of the company's stock, valued at approximately $5,056,359.60. This represents a 1.75% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 186,655 shares of company stock worth $6,868,636 in the last quarter.

Pharvaris Profile

Pharvaris N.V. is a biopharmaceutical company focused on developing oral therapies for hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent episodes of swelling. The company is headquartered in Zug, Switzerland, and was founded in 2015 by former executives from Pharming Group.

Pharvaris' lead investigational medicine is deucrictibant, an orally administered small-molecule bradykinin B2 receptor antagonist. The company is evaluating different formulations of deucrictibant for both on-demand treatment of HAE attacks and long-term prevention of attacks.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.